[HTML][HTML] Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment …
K Hummelink, M Muller, TC Linders… - ERJ Open …, 2019 - Eur Respiratory Soc
Objectives Molecular profiling of tumours has become the mainstay of diagnostics for
metastasised solid malignancies and guides personalised treatment, especially in nonsmall …
metastasised solid malignancies and guides personalised treatment, especially in nonsmall …
[HTML][HTML] Comparison of cytology, chest computed and positron emission tomography findings in malignant pleural effusion from lung cancer
C Brun, P Gay, M Cottier, G Karpathiou… - Journal of thoracic …, 2018 - ncbi.nlm.nih.gov
Background Malignant pleural effusion (MPE) is a common medical problem in lung cancer
(LC). Pleural fluid cytology (PFC), chest computed tomography (CCT) and positron emission …
(LC). Pleural fluid cytology (PFC), chest computed tomography (CCT) and positron emission …
Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion
A Marazioti, CA Kairi, M Spella, AD Giannou… - PLoS …, 2013 - journals.plos.org
Using genetic interventions, we previously determined that CC motif chemokine ligand 2
(CCL2) promotes malignant pleural effusion (MPE) formation in mice. Here we conducted …
(CCL2) promotes malignant pleural effusion (MPE) formation in mice. Here we conducted …
[HTML][HTML] Switching off malignant pleural effusion formation—fantasy or future?
M Spella, AD Giannou… - Journal of thoracic …, 2015 - ncbi.nlm.nih.gov
Malignant pleural effusion (MPE) is common and difficult to treat. In the vast majority of
patients the presence of MPE heralds incurable disease, associated with poor quality of life …
patients the presence of MPE heralds incurable disease, associated with poor quality of life …
Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: a systematic …
Objective To systematically review and meta-analyze published data about the diagnostic
performance of Fluorine-18-Fluorodeoxyglucose (18 F-FDG) positron emission tomography …
performance of Fluorine-18-Fluorodeoxyglucose (18 F-FDG) positron emission tomography …
Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation
JY Zou, AE Bella, ZG Chen, XQ Han… - Journal of …, 2014 - journals.sagepub.com
Objective A retrospective single-centre study to compare the clinical features of patients with
lung adenocarcinoma with and without epidermal growth factor receptor (EGFR) mutations …
lung adenocarcinoma with and without epidermal growth factor receptor (EGFR) mutations …
Upregulation of soluble B7-H3 in NSCLC-derived malignant pleural effusion: A potential diagnostic biomarker correlated with NSCLC staging
L Chen, G Zhang, S Sheng, Q Zhou, Y Pan, S Guan - Clinica Chimica Acta, 2016 - Elsevier
Background The B7 family member B7-H3 (CD276) is involved in tumor immunity including
Non-small-cell lung cancer (NSCLC). We have previously demonstrated an elevated …
Non-small-cell lung cancer (NSCLC). We have previously demonstrated an elevated …
Phenotypic and functional characterizations of CD8+ T cell populations in malignant pleural effusion
Y Zhang, W Li, J Zhai, Y Jin, L Zhang, C Chen - Experimental Cell …, 2022 - Elsevier
Malignant pleural effusions (MPE) are a common terminal pathway for many types of cancer,
especially non-small cell lung cancer (NSCLC). However, the phenotype and differentiation …
especially non-small cell lung cancer (NSCLC). However, the phenotype and differentiation …
Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients
X Ruan, Y Sun, W Wang, J Ye, D Zhang… - Oncology …, 2020 - spandidos-publications.com
Lung cancer is the most common type of cancer and the leading cause of cancer‑associated
death worldwide. Malignant pleural effusion (MPE), which is observed in~ 50% of advanced …
death worldwide. Malignant pleural effusion (MPE), which is observed in~ 50% of advanced …
Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study
Q Wei, T Deng, J Wu, H Zeng, C Qi, S Tan, Y Zhang… - BMC cancer, 2024 - Springer
Background Immune checkpoint inhibitors (ICI) combined with chemotherapy are efficacious
for treating advanced non-small cell lung cancer (NSCLC); however, the effectiveness of this …
for treating advanced non-small cell lung cancer (NSCLC); however, the effectiveness of this …